The Seventh Circuit denied reviving a Testosterone Replacement Therapy (TRT) lawsuit filed against Auxilium Pharmaceuticals Inc. linked to its drug Testim stating that the District Court prevented the key witness from testifying. The lawsuit filed by a plaintiff was selected for bellwether trial in the multidistrict litigation over alleged deep vein thrombosis (DVT), which he developed in 2013 due to Testim use. The Seventh Circuit asserted that the testimony from the expert witness that the plaintiff decided to use does not match with the facts of his case.
About 6,000 TRT cases are pending in the multidistrict litigation, alleging that the products led to complications like cardiac arrest, stroke, and sudden death. Other defendants in the litigation include Abbott Laboratories Inc., Pharmacia & Upjohn Inc., Pfizer Inc., Endo Pharmaceuticals Inc., Eli Lilly & Co., and Actavis Inc. In a recent announcement, Actavis Incorporation agreed to settle cases over its TRT drug Androderm, accusing them of failing to warn men about side effects.
